1616063-76-3

Upstream product

• 1616063-57-0 4-(2-(4-bromophenyl)-2-oxoethylamino)benzenesulfonamide 
• 1616063-59-2 4-(2-amino-4-(4-bromophenyl)-3-cyano-1H-pyrrol-1-yl)benzenesulfonamide 
• 1616063-60-5 ethyl N-(4-(4-bromophenyl)-3-cyano-1-(4-sulfamoylphenyl)-1H-pyrrol-2-yl)formimidate 
• 1616063-62-7 4-(3-amino-5-(4-bromophenyl)-4-imino-3,4-dihydropyrrolo[2,3-d]pyrimidin-7-yl)benzenesulfonamide 
• 91-56-5 indole-2,3-dione 
• 63-74-1 sulfanilamide 
• 99-73-0 para-bromophenacyl bromide 

Relevant academic research and scientific papers

Carbonic anhydrase inhibitors: Synthesis, molecular docking, cytotoxic and inhibition of the human carbonic anhydrase isoforms I, II, IX, XII with novel benzenesulfonamides incorporating pyrrole, pyrrolopyrimidine and fused pyrrolopyrimidine moieties

A series of novel pyrroles, pyrrolopyrimidines, pyrazolopyrrolopyrimidine, triazolopyrrolopyrimidines, tetrazolopyrrolopyrimidine, triazinopyrrolopyrimidines and pyrrolopyrimidotriazepines bearing the biologically active benzenesulfonamide moiety were synthesized by using pyrrole-o-amino-carbonitrile as key intermediate. All the synthesized compounds were evaluated for their in vitro carbonic anhydrase (CA, EC 4.2.1.1) inhibitory effects against the human (h) isoforms hCA I, II, IX and XII. Among the tested derivatives, compounds 16, 18 and 20-24 showed potent activity as inhibitors for the tumor associated transmembrane isoforms (hCA IX and XII) in the nanomolar and subnanomolar range, with high selectivity. All compounds underwent cytotoxic activity assays on human breast cancer cell line (MCF-7) showing effective activity, comparable to that of the clinically used drug doxorubicin.